about
Paralemmin interacts with D3 dopamine receptors: implications for membrane localization and cAMP signalingBif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagyNeurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomainsCeramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrestC(6)-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch-Injured ArteriesCeramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomainsRole of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.Sphingosine Kinase 1 Cooperates with Autophagy to Maintain Endocytic Membrane Trafficking.A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal AdenocarcinomaSuccessful chemoimmunotherapy against hepatocellular cancer in a novel murine model.Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemiaShort-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells.A novel biologically active acid stable liposomal formulation of docosahexaenoic acid in human breast cancer cell lines.Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemiaModification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.Lysosomal degradation of CD44 mediates ceramide nanoliposome-induced anoikis and diminished extravasation in metastatic carcinoma cells.The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.Formation and role of exosomes in cancer.Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.Diabetic retinopathy: seeing beyond glucose-induced microvascular disease.Use of high performance liquid chromatography-electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levelsCeramide modulates HERG potassium channel gating by translocation into lipid raftsPhosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway.Deregulated Akt3 activity promotes development of malignant melanoma.Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemiaCirculating sphingolipid biomarkers in models of type 1 diabetes.Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance.Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia.Sphingolipids as therapeutics.Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.Exogenous ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine expression.Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug deliveryAutophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis.Ceramide kinase regulates TNFα-stimulated NADPH oxidase activity and eicosanoid biosynthesis in neuroblastoma cellsDiabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy.Diabetes diminishes phosphatidic acid in the retina: a putative mediator for reduced mTOR signaling and increased neuronal cell death.Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer.Sphingolipids: regulators of crosstalk between apoptosis and autophagy
P50
Q24300112-E6E7C347-A9EB-4374-8D46-39376E0C15B4Q24306697-CC710608-7DF0-4DFD-B22E-C13747AAFC9EQ24310096-7B4D00C3-21D8-4179-85F1-D04C911B99E9Q28207697-EC8FD5A2-64A6-4110-9191-1E3E1C1D7A6AQ28392226-778679B0-6353-4093-B024-536A5A207053Q28572860-1E206935-F33C-48DB-9A2A-B4509B7851FDQ30274798-1FC322EA-12BA-4C18-A61A-5608CCAAE538Q30275525-44819BFE-4C16-4BAF-B155-28C28A9DFDF3Q30275702-665C23AE-98DD-4397-A2A8-22A2BFFE731BQ30276134-7875E056-AC0A-4494-BA1B-8AB633AE2ED9Q30276873-2741968D-2380-4183-ADD1-3325026FDEB6Q30277033-8E04A3A1-7BA6-41E2-A2C4-52495ECEAF17Q30277045-8272406A-1C9F-4BFD-8D66-8650E04D2B9EQ30278944-55D69310-A01F-466E-A921-A809D1297064Q30300370-2524CB2D-B7EA-45C2-98F2-2CA11628AED0Q30300775-67045AA3-7199-4515-984C-4307C694624CQ30301001-0E58CCF3-B345-4028-8214-59CC83484319Q30303067-98C4F3D2-0250-4CA7-B475-1F330D57BE03Q30353992-8CC02556-2DAC-4DC6-8CAB-D7F14AFC6217Q30356505-8E0D2C9C-B7A1-4EF7-A815-422AAF465C95Q33634194-33F4B208-D42B-4336-BB02-E7625A5EB3C2Q33995612-D927237F-BA17-4326-B743-A257C654185BQ34085728-3A535F65-6ADB-4EA4-B7F7-ACF506E1C779Q34355872-818E5D81-A311-4322-B53F-30D0D08AE05FQ34360352-38333748-FD30-438F-A454-80EDD3548BF8Q34560757-87E0AD07-845D-43E8-AAF5-A6C2DD40A54EQ34616639-DDA0557F-3789-4C42-A9DA-7F4D131735F4Q34975327-74584714-3F06-4A3C-8E2B-14A4B8C076C0Q35075838-2FF97B27-7EBD-4D5D-AFBB-190853FD6552Q35099451-ADA0BA37-CF4A-4211-ABB0-81F2C5C63128Q35212369-DD62C4E3-0A86-41A9-A8F5-D6E3E15C8F79Q35556455-0434E322-C690-4017-AF78-9F4CFCD33109Q35639693-BC6D87CB-4201-4BBA-8704-7C2C7A525A79Q35703862-A7ECE3AD-0F15-49D7-9AD7-B22A3607EAD7Q35874532-9CC2C1CD-91F8-4042-A38F-E8C0BFF4BE60Q35918569-8F25D2F2-F129-43F9-B708-8C921A382809Q36276111-432F7EBB-B6AA-47F5-827F-FAC68EC6A457Q36338100-B3D280EF-D9C0-475C-B881-EC2F232F9CD3Q36392653-B11FE088-4432-4C4D-8215-33B3A36492B0Q36462123-818910AC-7DF2-4E7B-BFB3-A8F17A6FD659
P50
description
researcher
@en
name
Mark Kester
@ast
Mark Kester
@ca
Mark Kester
@da
Mark Kester
@de
Mark Kester
@en
Mark Kester
@es
Mark Kester
@eu
Mark Kester
@fi
Mark Kester
@fr
Mark Kester
@hu
type
label
Mark Kester
@ast
Mark Kester
@ca
Mark Kester
@da
Mark Kester
@de
Mark Kester
@en
Mark Kester
@es
Mark Kester
@eu
Mark Kester
@fi
Mark Kester
@fr
Mark Kester
@hu
altLabel
Kester M
@en
Kester M.
@en
Kester
@en
M Kester
@en
M. Kester
@en
prefLabel
Mark Kester
@ast
Mark Kester
@ca
Mark Kester
@da
Mark Kester
@de
Mark Kester
@en
Mark Kester
@es
Mark Kester
@eu
Mark Kester
@fi
Mark Kester
@fr
Mark Kester
@hu